M&A - LIGAND PHARMACEUTICALS INC

Form Type: 8-K

Filing Date: 2025-04-17

Corporate Action: Merger

Type: New

Accession Number: 000088616325000020

Filing Summary: On April 17, 2025, Ligand Pharmaceuticals Incorporated and its wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc., entered into an Agreement and Plan of Merger with Channel Therapeutics Corporation. This merger will see Pelthos combine with a wholly-owned subsidiary of Channel as part of the Transaction. A joint press release detailing the Merger Agreement and the Transaction was issued by Ligand and Channel. This document includes forward-looking statements regarding the merger process, potential risks, and the implications for Ligand's operations and financial condition. Relevant exhibits were filed, including a press release dated the same day.